BioMarin Pharmaceutical (NASDAQ: BMRN) and Tokai Pharmaceuticals (NASDAQ:NVUS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Valuation and Earnings

This table compares BioMarin Pharmaceutical and Tokai Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
BioMarin Pharmaceutical $1.20 billion 13.24 -$106.70 million ($1.09) -83.18
Tokai Pharmaceuticals N/A N/A -$4.10 million N/A N/A

Tokai Pharmaceuticals has higher revenue, but lower earnings than BioMarin Pharmaceutical.

Volatility & Risk

BioMarin Pharmaceutical has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Tokai Pharmaceuticals has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Insider and Institutional Ownership

97.4% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 39.8% of Tokai Pharmaceuticals shares are held by institutional investors. 2.5% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 5.2% of Tokai Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioMarin Pharmaceutical and Tokai Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical 0 7 15 0 2.68
Tokai Pharmaceuticals 0 0 0 0 N/A

BioMarin Pharmaceutical currently has a consensus target price of $110.95, indicating a potential upside of 22.37%. Given BioMarin Pharmaceutical’s higher probable upside, equities research analysts plainly believe BioMarin Pharmaceutical is more favorable than Tokai Pharmaceuticals.

Profitability

This table compares BioMarin Pharmaceutical and Tokai Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical -15.54% -5.77% -4.00%
Tokai Pharmaceuticals N/A -138.81% -121.03%

Summary

BioMarin Pharmaceutical beats Tokai Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Tokai Pharmaceuticals Company Profile

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.